Natco Pharma Share Price Analyzed

Natco Pharma’s stock price jumped up on December 1, 2025, because a credit rating company, ICRA, said the company was still good at paying its debts. This news caused the stock to rise by 5% to ₹922.15 on the stock market. The company’s stock has gone up a lot since it hit its lowest point of the year.

Key Points

• ICRA upgraded Natco Pharma’s debt ratings, boosting investor confidence.
• Stock price rose 5% to ₹922.15 due to the positive rating.
• Company’s stock is up nearly 40% from its lowest price this year.
• Stock remains below its highest price from last year.
• Company’s EPS is high, indicating profitable operations.
• Significant trading volume of 3 million shares occurred on the market.

The stock price increased because ICRA, a company that checks how reliable businesses are, gave Natco Pharma a good rating. This made investors more confident, and the stock went up by 5% to ₹922.15. It’s gotten much better since it was at its lowest price during the year.

Natco Pharma’s stock price is currently above ₹914.85, a rise of 4.16% from the previous day. The stock market’s main index, the BSE Sensex, also went up. Lots of shares – almost 3 million – were bought and sold on the stock market, worth about ₹273.42 crore.

To understand the company’s finances, we can look at some important numbers. Natco Pharma has a good profit per share (EPS) of 85.79. It also has a good return on its investments (ROE) of 22.18. These numbers show that the company is doing well.

Here’s a breakdown of the key ratings from ICRA:

These ratings show that Natco Pharma is a reliable company, which makes its stock a good investment choice.

“A positive credit rating strengthens investor confidence and supports the company’s financial stability.”